A61P 25/04
Centrally acting analgesics
Official title: Centrally acting analgesics, e.g. opioids
A61P25/04 (Centrally acting analgesics) appears on 12,948 US grants and 16,541 published applications in this corpus.
Search patents in A61P- Granted patents
- 12,948
- Published applications
- 16,541
- Assignees
- 4,084
- Inventors
- 25,467
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 33 | 0 |
| 1977 | 38 | 0 |
| 1978 | 60 | 0 |
| 1979 | 37 | 0 |
| 1980 | 52 | 0 |
| 1981 | 69 | 0 |
| 1982 | 64 | 0 |
| 1983 | 54 | 0 |
| 1984 | 68 | 0 |
| 1985 | 95 | 0 |
| 1986 | 80 | 0 |
| 1987 | 78 | 0 |
| 1988 | 81 | 0 |
| 1989 | 115 | 0 |
| 1990 | 100 | 0 |
| 1991 | 108 | 0 |
| 1992 | 84 | 0 |
| 1993 | 90 | 0 |
| 1994 | 112 | 0 |
| 1995 | 105 | 0 |
| 1996 | 172 | 0 |
| 1997 | 269 | 0 |
| 1998 | 226 | 0 |
| 1999 | 224 | 0 |
| 2000 | 173 | 0 |
| 2001 | 229 | 75 |
| 2002 | 240 | 310 |
| 2003 | 234 | 531 |
| 2004 | 215 | 748 |
| 2005 | 194 | 713 |
| 2006 | 295 | 720 |
| 2007 | 325 | 766 |
| 2008 | 333 | 905 |
| 2009 | 422 | 1003 |
| 2010 | 501 | 1162 |
| 2011 | 590 | 1111 |
| 2012 | 743 | 981 |
| 2013 | 827 | 887 |
| 2014 | 824 | 884 |
| 2015 | 679 | 921 |
| 2016 | 597 | 855 |
| 2017 | 712 | 838 |
| 2018 | 552 | 648 |
| 2019 | 468 | 557 |
| 2020 | 395 | 475 |
| 2021 | 280 | 345 |
| 2022 | 202 | 288 |
| 2023 | 156 | 276 |
| 2024 | 119 | 237 |
| 2025 | 150 | 206 |
| 2026 | 79 | 99 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Injectable formulations in a method for treating pain6 Oct 2026US 12,751,943 B2Pelthos Therapeutics Inc.
- Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin6 Oct 2026US 12,751,960 B2Compass Pathfinder Limited
- N-formylhydroxylamines as neprilysin (NEP) inhibitors, in particular as mixed aminopeptidase N (APN) and neprilysin (NEP) inhibitors6 Oct 2026US 12,753,149 B2Kos Therapeutics, Inc.
- Use of dextromethorphan in combination with CYP2D6 and CYP3A4 enzyme inhibitors for the treatment of pain29 Sep 2026US 12,746,235 B2Biobina LLC
- Capsaicin analogs and uses thereof29 Sep 2026US 12,747,200 B2Young BioPharma, LLC
- Cis-8-(3,5-Difluorophenyl)-8-(dimethylamino)-1,3-diazaspiro[4.5]decan-2-one derivatives8 Oct 2026US 2026/0308140 A1Gruenenthal GmbH
- Crispr-cas genome engineering via a modular aav delivery system8 Oct 2026US 2026/0308630 A1The Regents of the University of California
- Fluorinated mu-opioid receptor agonists10 Sep 2026US 2026/0265205 A1The United State of America, as represented by the Secretary, Department of Health and Human
- Long-acting k-opioid receptor agonist10 Sep 2026US 2026/0265301 A1Chengdu Aoda Biotechnology Co., Ltd
- Polypeptide pharmaceuticals27 Aug 2026US 2026/0248925 A1Mederis Diabetes LLC
Most cited
By later US patents
- Modular infusion device and method1,554US 6,749,587 B2Insulet Corporation · 2004
- Gum pad for delivery of medication to mucosal tissues1,140US 6,319,510 B12001
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions930US 6,248,363 B1Lipocine Inc. · 2001
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions684US 6,923,988 B2Lipocine Inc. · 2005
- Method of moving a delivery member of a dispensing device for administration of oral transmucosal dosage forms654US 8,499,966 B2AcelRx Pharmaceuticals, Inc. · 2013